Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to purchase up to $700 million worth of the digital currency BNB following its recent all-time high. The company is raising approximately $520 million through an equity credit line from an unnamed institutional investor, in addition to a $20 million stock-purchase agreement with Build and Build Corp. This move marks a significant strategy for the company, as it aims to enhance its balance sheet with digital assets. BNB has a market cap of $106.9 billion and recently traded around $769 after climbing to $808. Windtree’s decision aligns with a trend among publicly traded companies investing in cryptocurrencies to boost their stock valuations. Despite a current 5% drop in Windtree’s stock value, the company has witnessed a substantial 162% increase over the past month.

Source 🔗